Related references
Note: Only part of the references are listed.Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS
Giulia Biffi et al.
PHYSIOLOGICAL REVIEWS (2021)
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Jingjing Qu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
B7-H3: An Attractive Target for Antibody-based Immunotherapy
Filippos Kontos et al.
CLINICAL CANCER RESEARCH (2021)
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
Shivani Srivastava et al.
CANCER CELL (2021)
Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
Marsha Pellegrino et al.
CELLS (2021)
Establishment of Criteria for Molecular Differential Diagnosis of MPLC and IPM
Xiaohui Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
Jie Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity
Mary K. McKenna et al.
MOLECULAR THERAPY (2021)
Navigating CAR-T cells through the solid-tumour microenvironment
Andrew J. Hou et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies
Shouheng Lin et al.
FRONTIERS IN IMMUNOLOGY (2021)
Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
Toon Allaeys et al.
CANCERS (2021)
Control of the activity of CAR-T cells within tumours via focused ultrasound
Yiqian Wu et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
Fengzhen Mo et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson et al.
NATURE REVIEWS CANCER (2021)
Current Progress in CAR-T Cell Therapy for Hematological Malignancies
Donglei Han et al.
JOURNAL OF CANCER (2021)
Mesothelin-targeted CAR-T cell therapy for solid tumors
Astero Klampatsa et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy
Preetesh Jain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
In search of definitions: Cancer-associated fibroblasts and their markers
Martin Nurmik et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling
Zurong Wan et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
Eileen McGowan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells
Chuang Sun et al.
CANCER CELL (2020)
Current challenges and emerging opportunities of CAR-T cell therapies
Teresa R. Abreu et al.
JOURNAL OF CONTROLLED RELEASE (2020)
CAR T cells: continuation in a revolution of immunotherapy
Anurag K Singh et al.
LANCET ONCOLOGY (2020)
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
Aman P. Singh et al.
MABS (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
Norris Lam et al.
NATURE COMMUNICATIONS (2020)
Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA)
Magdalena Niemira et al.
CANCERS (2020)
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185)
Xin Li et al.
THORACIC CANCER (2020)
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
Simona Porcellini et al.
FRONTIERS IN IMMUNOLOGY (2020)
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
Benjamin Philipson et al.
SCIENCE SIGNALING (2020)
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
Yu Chen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Janina Henze et al.
CANCERS (2020)
Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
Ewelina Grywalska et al.
CELLS (2020)
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold
Kento Fujiwara et al.
CELLS (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties
Kento Fujiwara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
Chuan Tong et al.
BLOOD (2020)
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong et al.
CANCER CELL (2020)
Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Ming Liu et al.
ONCOGENESIS (2020)
Use of Cell and Genome Modification Technologies to Generate Improved Off-the-Shelf CAR T and CAR NK Cells
Michael A. Morgan et al.
FRONTIERS IN IMMUNOLOGY (2020)
A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes
Daniel Schaefer et al.
FRONTIERS IN IMMUNOLOGY (2020)
LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer
Ziming Hu et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman et al.
EBIOMEDICINE (2020)
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
Andreas Saltos et al.
FRONTIERS IN ONCOLOGY (2020)
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Luis Gerardo Rodriguez-Lobato et al.
FRONTIERS IN ONCOLOGY (2020)
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
Le Qin et al.
BIOMARKER RESEARCH (2020)
Recent advances in CAR-T cell engineering
Ruihao Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis
Jianjie Li et al.
BMC CANCER (2020)
CAR-T cell therapy for lung cancer: a promising but challenging future
Shupeng Zhong et al.
JOURNAL OF THORACIC DISEASE (2020)
Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis
Ze-Bo Jiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela Maus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Engineering better chimeric antigen receptor T cells
Hao Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Functional and clinical significance of ROR1 in lung adenocarcinoma
Schiavone Giovanna et al.
BMC CANCER (2020)
CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
Anna Christina Dragon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
Ranya Barayan et al.
JOURNAL OF THORACIC DISEASE (2020)
A framework for advancing our understanding of cancer-associated fibroblasts
Erik Sahai et al.
NATURE REVIEWS CANCER (2020)
CAR T-Cell-Associated Neurotoxicity Current Management and Emerging Treatment Strategies
Amanda M. Rivera et al.
CRITICAL CARE NURSING QUARTERLY (2020)
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
Meijia Yang et al.
THERANOSTICS (2020)
Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment
Stuart J. Carter et al.
RHEUMATOLOGY (2019)
Cancer-associated fibroblasts in gastrointestinal cancer
Hiroki Kobayashi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang et al.
FRONTIERS OF MEDICINE (2019)
Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC
Qun Gao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Urs B. Hagemann et al.
CLINICAL CANCER RESEARCH (2019)
Emerging therapies for small cell lung cancer
Sen Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Yushu Joy Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Next-Generation Cancer Immunotherapy Targeting Glypican-3
Yasuhiro Shimizu et al.
FRONTIERS IN ONCOLOGY (2019)
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel et al.
BIODRUGS (2019)
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
Annie Roys et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance
Smita S. Chandran et al.
IMMUNOLOGICAL REVIEWS (2019)
DLL3: an emerging target in small cell lung cancer
Dwight H. Owen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
Yuan Mao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CAR-T the living drugs, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Delong Liu
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Recent updates on CAR T clinical trials for multiple myeloma
Quande Lin et al.
MOLECULAR CANCER (2019)
Significance of TIM3 expression in cancer: From biology to the clinic
Cinzia Solinas et al.
SEMINARS IN ONCOLOGY (2019)
Engineered T Cell Therapy for Cancer in the Clinic
Lijun Zhao et al.
FRONTIERS IN IMMUNOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
A positive feedback loop between ZNF205-AS1 and EGR4 promotes non-small cell lung cancer growth
Susu He et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
Sophia Stock et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
c-Jun overexpression in CAR T cells induces exhaustion resistance
Rachel C. Lynn et al.
NATURE (2019)
Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
Lin Ye et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (vol 3, e120505, 2018)
Alfred L. Garfall et al.
JCI INSIGHT (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Immunotherapy- Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites
Chandan Sanghera et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers
Aiten M. Soliman et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe et al.
JCI INSIGHT (2019)
A compound chimeric antigen receptor strategy for targeting multiple myeloma
K. H. Chen et al.
LEUKEMIA (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Driving CARs on the uneven road of antigen heterogeneity in solid tumors
Nan Chen et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Targeting fibroblast activation protein in cancer - Prospects and caveats
Petr Busek et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2018)
4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
Ashley V. Menk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Ying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
T cell senescence and CAR-T cell exhaustion in hematological malignancies
Dimitri Kasakovski et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Brandon Golding et al.
MOLECULAR CANCER (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Targeting the tumour stroma to improve cancer therapy
Kenneth C. Valkenburg et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models
Denise L. Crossland et al.
ONCOGENE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
Ning Li et al.
TRANSLATIONAL ONCOLOGY (2018)
Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer
Wenqi Chu et al.
BIOSCIENCE TRENDS (2018)
Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice
He Li et al.
CELL DEATH & DISEASE (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
Comparison and discussion of the treatment guidelines for small cell lung cancer
Honglin Zhao et al.
THORACIC CANCER (2018)
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
Mauro P. Avanzi et al.
CELL REPORTS (2018)
Anti-Angiogenics: Their Value in Lung Cancer Therapy
Melanie Janning et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Exploiting Nanobodies' Singular Traits
Jessica R. Ingram et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Erratum to: Kiesgen S, Chicaybam L, Chintala N.K, Adusumilli P.S. Chimeric antigen receptor (CAR) t-cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16-26.
Journal of Thoracic Oncology (2018)
Tumors evading CARs-the chase is on
Sarwish Rafiq et al.
NATURE MEDICINE (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Emerging Cellular Therapies for Cancer
Sonia Guedan et al.
Annual Review of Immunology (2018)
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Noelle Frey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lydia Lee et al.
BLOOD (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Sonia Guedan et al.
JCI INSIGHT (2018)
Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
Ashwini Balakrishnan et al.
CLINICAL CANCER RESEARCH (2017)
Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells
Elizabeth Siegler et al.
HUMAN GENE THERAPY (2017)
Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers
Johan C. K. Tay et al.
IMMUNOTHERAPY (2017)
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Paul A. Beavis et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
Iulia Diaconu et al.
MOLECULAR THERAPY (2017)
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering
Xiaolu Han et al.
MOLECULAR THERAPY (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Treatment advances in small cell lung cancer (SCLC)
Saiama N. Waqar et al.
PHARMACOLOGY & THERAPEUTICS (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
IN-DEPTH REVIEW: CHIMERIC ANTIGEN RECEPTOR T CELLS-BASED THERAPIES CAR T-cell therapy for lung cancer and malignant pleural mesothelioma
Masha Zeltsman et al.
TRANSLATIONAL RESEARCH (2017)
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
Melinda Mata et al.
CANCER DISCOVERY (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Markus Chmielewski et al.
CELL REPORTS (2017)
MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer
Audrey Bouillez et al.
ONCOIMMUNOLOGY (2017)
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Hong Jiang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome
Deborah R. Caswell et al.
BMC MEDICINE (2017)
Dysfunctional T cell metabolism in the tumor microenvironment
Kathryn E. Beckermann et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
Yozo Nakazawa et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
De-Gang Song et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Enxiu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer
Melissa L. Johnson et al.
SEMINARS IN ONCOLOGY (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Adoptive Immunotherapy with Redirected T Cells Produces CCR7- Cells That Are Trapped in the Periphery and Benefit from Combined CD28-OX40 Costimulation
Andreas A. Hombach et al.
HUMAN GENE THERAPY (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach
Connie P. M. Duong et al.
PLOS ONE (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma
Tomoya Yamaguchi et al.
CANCER CELL (2012)
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
Helene Salmon et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Andreas A. Hombach et al.
ONCOIMMUNOLOGY (2012)
Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
De-Gang Song et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
John S. Bridgeman et al.
JOURNAL OF IMMUNOLOGY (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Share Paper
